Alvin Gutierrez, MD
Internal Medicine · Pembroke Pines, FLNPI 1346231420
Payments from drug & device makers
Across 205 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$737
- Exact Sciences$273
- Lilly USA, LLC$255
- Abbott$254
- Boehringer Ingelheim$200
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,381100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $1,136 |
| AstraZeneca | 33 | $737 |
| Exact Sciences | 11 | $273 |
| Lilly USA, LLC | 15 | $255 |
| Abbott | 11 | $254 |
| Boehringer Ingelheim | 8 | $200 |
| Pfizer | 7 | $158 |
| Bayer | 5 | $138 |
| Amgen | 7 | $122 |
| Dexcom, Inc. | 4 | $102 |
| Johnson & Johnson | 6 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $98 |
| Avanir Pharmaceuticals, Inc. | 6 | $94 |
| Merck | 5 | $92 |
| GSK | 3 | $75 |
| Amarin Pharma, Inc. | 3 | $53 |
| AbbVie(2 entities) | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 2 | $48 |
| Corcept Therapeutics | 2 | $47 |
| Antares Pharma, Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| Hologic Sales And Service, LLC | 1 | $44 |
| Astellas Pharma US Inc | 1 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Mannkind Corporation | 2 | $34 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Halozyme Inc | 1 | $23 |
| IBSA Pharma Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Shield Therapeutics Inc | 1 | $20 |
| Eisai Inc. | 1 | $17 |
How this compares
$4,394 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 85 | $111,495 |
| JardianceEmpagliflozin | 83 | $94,124 |
| JanuviaSitagliptin Phosphate | 54 | $64,216 |
| EliquisApixaban | 46 | $58,188 |
| OzempicSemaglutide | 61 | $55,928 |
| RybelsusSemaglutide | 35 | $49,359 |
| MounjaroTirzepatide | 35 | $36,652 |
| XareltoRivaroxaban | 26 | $30,119 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $23,682 |
| EntrestoSacubitril/Valsartan | 16 | $20,367 |
| TradjentaLinagliptin | 12 | $17,457 |
| LinzessLinaclotide | 13 | $16,049 |
| RestasisCyclosporine | 22 | $14,876 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $13,814 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $13,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $200 | $135,263116 claims |
| AstraZenecaFarxiga | $737 | $111,49585 claims |
| Novo NordiskOzempic, Rybelsus | $1,136 | $105,28896 claims |
| MerckJanuvia, Janumet | $92 | $78,03073 claims |
| PfizerEliquis | $158 | $58,18846 claims |
| Lilly USA, LLCMounjaro | $255 | $36,65235 claims |
| AbbVieLinzess, Restasis, Synthroid | $52 | $33,08254 claims |
| Johnson & JohnsonXarelto | $99 | $30,11926 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $2,82211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pembroke Pines
- Jaynier MoyaPembroke Pines$45.4M
- Yanely Pineiro PueblaPembroke Pines$12.4M
- Armando de FeriaPembroke Pines$11.8M
- Maria BermudezPembroke Pines$10.2M
- Robert PerryPembroke Pines$9.2M
- Ernesto FuentesPembroke Pines$9M
- Giralt Yanez RamosPembroke Pines$5.5M
- Kenneth BlazePembroke Pines$4.3M
- Reynold Duarte MartinezPembroke Pines$4.1M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.